Deals channel feed

Dean Li in­vites an­oth­er un­der-the-radar biotech to Mer­ck­'s deal­mak­ing ta­ble as Am­ath­us signs neu­rode­gen­er­a­tion pact

5 years ago

Mon­tre­al AI start­up with a tout­ed ad­vi­sor li­cens­es its 'few-shot' plat­form to Re­pare for syn­thet­ic lethal­i­ty mol­e­cules

5 years ago
Discovery

With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to Glob­al Blood Ther­a­peu­tics

5 years ago

Ab­b­Vie looks to shed Al­ler­gan's lega­cy wom­en's health unit as it hun­kers down for Hu­mi­ra biosim dooms­day — re­port

5 years ago

Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

5 years ago
People

Gilead, Mer­ck put aside ri­val­ry to chal­lenge Glax­o­SmithK­line for long-act­ing HIV meds

5 years ago

Roche drops $1.85B for Gen­Mark's test­ing tech as pan­dem­ic, an­tibi­ot­ic re­sis­tance threats loom

5 years ago

Take­da goes all in with build-to-buy play, pick­ing up Mav­er­ick and its clin­ic-ready T cell en­gagers for $525M

5 years ago

Fur­ther set­ting the stage for go­ing pub­lic, Vivek Ra­maswamy’s Roivant read­ies a deal to buy up a Vant’s stock — cheap

5 years ago

Jazz CEO Bruce Cozadd cam­paigned for 6 months to buy GW Phar­ma. A 90% pre­mi­um sealed the deal — along with $17.6M in ‘re­ten­tion’ in­cen­tives

5 years ago

Af­ter three years of courtship (and turn­downs), Mer­ck pounced on the first glance of clin­i­cal da­ta in $1.85B Pan­dion takeover

5 years ago

Am­gen snaps up can­cer drug play­er Five Prime, adding PhI­II-ready FGFR2b drug in $2B M&A play

5 years ago

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

5 years ago

Ab­b­Vie tees up a biotech buy­out af­ter siz­ing up their Parkin­son's drug spun out of Ke­van Shokat's lab

5 years ago

A 'love sto­ry': WuXi AppTec wraps UK-based CRO in­to its cell and gene ther­a­py unit

5 years ago
Outsourcing
Manufacturing

Pre­ci­sion in­flam­ma­tion drugs? Yale spin­out Ar­ti­zan clinch­es $11M and Bio­haven deal to sin­gle out bad bac­te­ria

5 years ago
Financing

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

5 years ago
China
Pharma

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

5 years ago
R&D

Roche and Genen­tech re­searchers plot $53M dis­cov­ery quest aimed at spark­ing a 'Holy moly' piv­ot in neu­ro R&D

5 years ago
R&D

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

5 years ago

Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

5 years ago
Pharma

In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sci­ences to fo­cus on de­cen­tral­ized clin­i­cal work

5 years ago

Biotech up­start adds a failed Mer­ck KGaA drug to the pipeline, map­ping new com­bo ap­proach to MAPK path­way

5 years ago

Beam turns its soar­ing val­u­a­tion in­to new as­sets, buy­ing out an un­der-the-radar spin­out and their gene de­liv­ery tech

5 years ago
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times